Successful #Tepotinib Treatment in MET Exon 14 Skipping Mutation-Positive Lung #Adenocarcinoma With Idiopathic Pulmonary Fibrosis Through #Nintedanib Combination
onlinelibrary.wiley.com/doi/10.1002/...
#IPF
New research from the #VISION trial of #tepotinib in #NSCLC with #METex14 skipping highlights key differences when patients are identified by LBxvs TBx.
➡️ #Tepotinib showed robust efficacy regardless of biopsy type
@christianrolfo.bsky.social @oncoalert.bsky.social
2024 approvals: Summary of 14 new drugs/indications in #LungCancer by FDA
1. #Tepotinib
2. #Osimertinib x2
3. #Alectinib
4. #Tarlatamab
5. #Zenocutuzumab
6. #Durvalumab x2
7. #Amivantamab x2
8. #Nivolumab (now SubQ)
9. #Ensartinib
#lcsm #OncSky #MedSky #Cancer
